2.84
2.84 (0%)
As of Apr 17, 2025
Kodiak Sciences Inc. [KOD]
Source:
Company Overview
Kodiak Sciences Inc. has developed a new technology platform, the Antibody Biopolymer Conjugate (“ABC”) Platform, for retinal medicines.
| Country | United States |
| Headquarters | palo alto, california |
| Phone Number | (650) 281-0850 |
| Industry | manufacturing |
| CEO | Victor Perlroth |
| Website | kodiak.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-186.8 |
| Net Income | $-176.2 |
| Net Cash | $-117.6 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -43.2% |
| Profit as % of Stockholder Equity | -117.3% |
Management Effectiveness
| Return on Equity | -117.3% |
| Return on Assets | -52.5% |
| Turnover Ratio | |
| EBITA | $-186.8 |
Balance Sheet and Cash Flow Measures
| Total Assets | $335.6 |
| Total Liabilities | $185.3 |
| Operating Cash Flow | $-117.3 |
| Investing Cash Flow | $-0.8 |
| Financing Cash Flow | $0.5 |
